NASDAQ:PTIE - Pain Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.21 -0.02 (-0.90 %) (As of 07/22/2018 04:42 AM ET)Previous Close$2.21Today's Range$2.20 - $2.2852-Week Range$2.03 - $12.80Volume77,888 shsAverage Volume469,016 shsMarket Capitalization$15.38 millionP/E Ratio-1.21Dividend YieldN/ABeta2.7 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas. Receive PTIE News and Ratings via Email Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:PTIE CUSIP69562K10 Webwww.paintrials.com Phone512-501-2444 Debt Debt-to-Equity RatioN/A Current Ratio14.51 Quick Ratio14.51 Price-To-Earnings Trailing P/E Ratio-1.21 Forward P/E Ratio-1.34 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.47 per share Price / Book1.50 Profitability EPS (Most Recent Fiscal Year)($1.82) Net Income$-11,910,000.00 Net MarginsN/A Return on Equity-101.55% Return on Assets-93.41% Miscellaneous Employees9 Outstanding Shares6,900,000Market Cap$15.38 Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions What is Pain Therapeutics' stock symbol? Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE." When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work? Shares of Pain Therapeutics reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split. How were Pain Therapeutics' earnings last quarter? Pain Therapeutics, Inc. (NASDAQ:PTIE) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.33. View Pain Therapeutics' Earnings History. When is Pain Therapeutics' next earnings date? Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Pain Therapeutics. What is the consensus analysts' recommendation for Pain Therapeutics? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pain Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Pain Therapeutics' key competitors? Some companies that are related to Pain Therapeutics include Evofem Biosciences (EVFM), Novus Therapeutics (NVUS), Zosano Pharma (ZSAN), Celsion (CLSN), IntelGenx Technologies (IGXT), Addex Pharmaceuticals (ADDXF), Imprimis Pharmaceuticals (IMMY), Heat Biologics (HTBX), vTv Therapeutics (VTVT), Moleculin Biotech (MBRX), Evoke Pharma (EVOK), AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Acerus Pharmaceuticals (TRLPF) and Capricor Therapeutics (CAPR). Who are Pain Therapeutics' key executives? Pain Therapeutics' management team includes the folowing people: Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs Has Pain Therapeutics been receiving favorable news coverage? Media headlines about PTIE stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Pain Therapeutics? Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pain Therapeutics' stock price today? One share of PTIE stock can currently be purchased for approximately $2.21. How big of a company is Pain Therapeutics? Pain Therapeutics has a market capitalization of $15.38 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe. How can I contact Pain Therapeutics? Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444. MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 103 (Vote Outperform)Underperform Votes: 141 (Vote Underperform)Total Votes: 244MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?